J.P. Morgan: GenScript bets on AI drug discovery with capacity expansion; related revenue projected to reach 2 to 4 times its 2026 level in 2027

Why is the 2027 growth outlook in focus?

JPMorgan sees GenScript’s 2027 revenue growth as a key point of debate. It expects 2027 revenue from the company’s AI drug discovery and development (AIDD) business to reach 2 to 4 times its 2026 level and potentially exceed the bank’s previous forecast of 108% year-on-year growth; the bank also believes the company could exceed its fiscal 2026 revenue guidance.
The 4-times outcome is a conditional optimistic scenario: capacity must expand at full speed, utilization must remain high in 2027, and prices must remain stable. In that case, average capacity for the full year could reach 4 times its 2026 level.
The investor day provided limited new financial and order guidance, and management said little about revenue growth in 2027. JPMorgan believes this may explain the company’s share price falling more than 7% that afternoon; the Hang Seng China Healthcare Index fell 1.3% over the same period.

The company presented an interval of 10 to 12 days between repeat AIDD purchases, versus about 30 days for traditional services, making order frequency approximately 2.5 times that of the latter; 70% of the order backlog comes from customers with signed master service agreements.
Management estimates the addressable market for the life sciences group’s AIDD services at approximately 1 billion US dollars in 2026, implying a compound annual growth rate of 50% to 80% through 2029. This market definition excludes customers’ internal validation and downstream development of AI-discovered drugs.
AI allows customers to explore more targets, molecular modalities and candidates, while validation extends from initial binding confirmation to multiple steps including functional assessment. Better candidate screening may reduce the volume tested per batch, but faster iteration could still increase total testing volume over the year.

Management plans to at least double related protein expression capacity every 3 to 6 months and schedule deployment according to peak customer demand. Upgrading processes from 96-well to 384-well formats and gradually reducing reaction volumes could allow more drug candidates to be processed while reducing reagent consumption per experiment.
Expansion requires more than additional equipment: quality control, downstream testing, instrument precision and scheduling must also keep pace for faster protein production to genuinely shorten customer timelines.
Of the proceeds from the equity financing in September 2026, 90% will be used for AIDD. Management expects the new capacity to be at least 1.5 times as efficient as the traditional model, with a payback period of 1 to 2 years, versus 2 to 3 years for the traditional model; actual returns depend on utilization.

Management expects profit to continue growing faster than revenue in the second half of 2026. However, JPMorgan’s model forecasts group revenue of 909 million US dollars in 2026, down 5.3% from 960 million US dollars in 2025; adjusted EBITDA is forecast at 212 million US dollars, below 359 million US dollars in 2025.
The bank forecasts operating cash flow of 196 million US dollars in 2026, below 326 million US dollars in 2025; free cash flow to the firm is forecast to fall from 182 million US dollars to 15 million US dollars. The company’s cell therapy business was recently deconsolidated, and its approximately 45% stake in Legend Biotech is now accounted for under the equity method.
Longer-term opportunities come from services such as cell lines, processes and formulations needed once projects enter later development. Management says most AIDD activity remains concentrated in the discovery stage, and JPMorgan expects projects may take 2 to 3 years to move from initial discovery into development.